45 episodes

PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

PeerVoice Heart & Lung Audio PeerVoice

    • Science
    • 5.0 • 1 Rating

PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

    Jonathan W. Goldman, MD - Don’t Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC

    Jonathan W. Goldman, MD - Don’t Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC

    Visit https://www.peervoice.com/HPP860 to view the entire programme with slides. After completing “Jonathan W. Goldman, MD - Don’t Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC”, participants will be able to: Differentiate between pathophysiology of MET alterations in patients with NSCLC and the recommended strategies for their detection; Apply best practices to overcome challenges in the identification of patients with NSCLC and MET vulnerabilities; and Summarize current and emerging strategies for targeting MET alterations as a therapeutic vulnerability in patients with NSCLC.

    • 57 min
    Javed Butler, MD, MPH, MBA - Practical Perspectives and Straightforward Strategies for Optimising GDMT in HFrEF: The Role of ARNI as a Fundamental Building Block

    Javed Butler, MD, MPH, MBA - Practical Perspectives and Straightforward Strategies for Optimising GDMT in HFrEF: The Role of ARNI as a Fundamental Building Block

    Visit https://www.peervoice.com/QJJ860 to view the entire programme with slides. After completing “Javed Butler, MD, MPH, MBA - Practical Perspectives and Straightforward Strategies for Optimising GDMT in HFrEF: The Role of ARNI as a Fundamental Building Block”, participants will be able to: Explain the role of combination angiotensin receptor neprilysin inhibitor therapy (ARNI) as a component of guideline-directed medical therapy (GDMT) in heart failure (HF); Formulate practical strategies for incorporating renin-angiotensin-aldosterone system (RAAS) inhibition, including ARNI, in management plans for patients with HF; and Apply recommended monitoring and management strategies to optimise the safety and efficacy of RAAS inhibition, including ARNI, in HF.

    • 45 min
    Wisia Wedzicha, MD, FRCP - Taking the Evidence from Paper to Practice: Shared Perspectives on Practical Considerations in Comprehensive COPD Care

    Wisia Wedzicha, MD, FRCP - Taking the Evidence from Paper to Practice: Shared Perspectives on Practical Considerations in Comprehensive COPD Care

    Visit https://www.peervoice.com/ZFW860 to view the entire programme with slides. After completing “Wisia Wedzicha, MD, FRCP - Taking the Evidence from Paper to Practice: Shared Perspectives on Practical Considerations in Comprehensive COPD Care”, participants will be able to: Summarise key data which informs guideline-driven interventions for patients with chronic obstructive pulmonary disease (COPD); Identify treatable traits which can guide need for non-pharmacologic interventions and selection of pharmacotherapy, including triple therapy, for patients with COPD; and Use patient- and disease-specific considerations and treatable traits to guide comprehensive management strategies for patients with COPD.

    • 23 min
    George Kassianos, CBE, MD (Hons), FRCGP / Gili Regev-Yochay, MD - Current 2024 COVID-19 Vaccination Campaign: The Evidence Supporting the Call to Action

    George Kassianos, CBE, MD (Hons), FRCGP / Gili Regev-Yochay, MD - Current 2024 COVID-19 Vaccination Campaign: The Evidence Supporting the Call to Action

    Visit https://www.peervoice.com/BSG860 to view the entire programme with slides. After completing “George Kassianos, CBE, MD (Hons), FRCGP / Gili Regev-Yochay, MD - Current 2024 COVID-19 Vaccination Campaign: The Evidence Supporting the Call to Action”, participants will be able to: Summarise the evidence supporting the need for the current 2024 COVID-19 vaccination campaign for older adults and vulnerable individuals; and Outline the key recommendations by the World Health Organization (WHO) and European Centre for Disease Prevention and Control (ECDC) on the current 2024 COVID-19 vaccination roll-out.

    • 11 min
    David M. G. Halpin, MB BS, DPhil, FERS - The Case for Improved Care in COPD: Appreciating COPD as a Leading Cause of Disability and Death

    David M. G. Halpin, MB BS, DPhil, FERS - The Case for Improved Care in COPD: Appreciating COPD as a Leading Cause of Disability and Death

    Visit https://www.peervoice.com/UWS860 to view the entire programme with slides. After completing “David M. G. Halpin, MB BS, DPhil, FERS - The Case for Improved Care in COPD: Appreciating COPD as a Leading Cause of Disability and Death”, participants will be able to: Recognise current unmet needs in the management of chronic obstructive pulmonary disease (COPD); Explain the rationale for early interventions, including both non-pharmacologic and pharmacologic, to improve control of symptoms and reduce exacerbations in patients with COPD; and Apply treatment guidelines for key non-pharmacologic and pharmacologic interventions in the management of patients with COPD.

    • 18 min
    Perry Elliott, MD, FRCP - What’s New and What’s Next? Expanding Our Understanding of HCM in 2023

    Perry Elliott, MD, FRCP - What’s New and What’s Next? Expanding Our Understanding of HCM in 2023

    Visit https://www.peervoice.com/UET860 to view the entire programme with slides. After completing “Perry Elliott, MD, FRCP - What’s New and What’s Next? Expanding Our Understanding of HCM in 2023”, participants will be able to: Discuss emerging clinical data related to the management of hypertrophic cardiomyopathy (HCM); Describe the latest updates on guideline recommendations for provision of evidence-based care for patients with HCM; and Use emerging clinical data and latest updates on guideline recommendations to manage patients with HCM.

    • 24 min

Customer Reviews

5.0 out of 5
1 Rating

1 Rating

Top Podcasts In Science

Hidden Brain
Hidden Brain, Shankar Vedantam
Something You Should Know
Mike Carruthers | OmniCast Media | Cumulus Podcast Network
Radiolab
WNYC Studios
Reinvent Yourself with Dr. Tara
Dr. Tara Swart Bieber
Ologies with Alie Ward
Alie Ward
StarTalk Radio
Neil deGrasse Tyson

More by PeerVoice

PeerVoice Endocrinology & Metabolic Disorders Audio
PeerVoice
PeerVoice Internal Medicine Audio
PeerVoice
PeerVoice Immunology & Infectious Disease Video
PeerVoice
PeerVoice Oncology & Haematology Video
PeerVoice
PeerVoice Oncology & Haematology Audio
PeerVoice
PeerVoice Digestive Diseases Audio
PeerVoice